Literature DB >> 4053442

Effect of the intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits.

D R Bard, C G Knight, D P Page-Thomas.   

Abstract

The treatment of rheumatoid arthritis by radiosynovectomy has been restricted by the difficulty of preventing leakage of the radioisotope from the joint cavity. We have previously shown that this leakage can be reduced to very low levels by delivering the radioisotope in liposomes containing the lipophilic chelator, 3-cholesteryl 6-[N'-iminobis-(ethylenenitrilo)tetraacetic acid]hexyl ether. The present study investigates the effectiveness of the beta-emitting isotope lutetium-177, delivered in chelator liposomes, in treating an experimental arthritis in rabbits. Chelator liposomes containing 0.35 mCi, 0.175 mCi Or 0.087 mCi of the isotope were injected into the synovial cavities of the knees of rabbits with an established experimental arthritis. The retention of the lutetium and the progress of the arthritis were followed for 47 days, and samples of the joint tissues were taken for histology at the end of the experiment. Results showed that losses of radioactivity averaged less than 1% per day over 47 days and that joints treated with 0.175 mCi showed significant reductions in both diameter and surface temperature compared with controls treated with a non-radioactive preparation. Post-mortem histology revealed that, whereas control joints showed a highly active synovitis, synovia of joints treated with 0.175 or 0.35 mCi lutetium-177 had very little inflammatory activity. Although some joints which had received 0.35 mCi showed signs of damage to the articular cartilage, this damage was not apparent wih either of the two lower doses. We conclude that, in this animal model, chelator liposomes complexed with a suitable radioisotope are capable of effecting an efficient synovectomy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053442

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

Review 1.  Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective.

Authors:  R M Fielding
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 2.  Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Authors:  Ashutosh Dash; Maroor Raghavan Ambikalmajan Pillai; Furn F Knapp
Journal:  Nucl Med Mol Imaging       Date:  2015-02-17

Review 3.  Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Authors:  B L R Kam; J J M Teunissen; E P Krenning; W W de Herder; S Khan; E I van Vliet; D J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

4.  Challenges and future options for the production of lutetium-177.

Authors:  W V Vogel; S C van der Marck; M W J Versleijen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07       Impact factor: 9.236

5.  Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.

Authors:  Christine Rangger; Anna Helbok; Elisabeth von Guggenberg; Jane Sosabowski; Thorsten Radolf; Ruth Prassl; Fritz Andreae; Gudrun C Thurner; Roland Haubner; Clemens Decristoforo
Journal:  Int J Nanomedicine       Date:  2012-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.